After finding success in the emerging sector of semaglutide drugs, Novo Nordisk's latest work toward development of it in pill form has shown results that are even better than Wegovy when it comes to shedding weight.
The drugmaker announced topline results from its phase 1 trial of its Amycretin pill on March 7, and following the announcement, Novo Nordisk shares jumped 7.5%, according to The Wall Street Journal.
In the trial, patients taking Amycretin lost about 13% of their body weight in 12 weeks — more than double the weight lost during the same time period with Wegovy, which was about 6%.
The pill is taken once daily and is slated to head into phase 2 trials later this year, the Journal reported. However, Barclays analysts wrote in a note that Novo Nordisk has "not ruled out going [straight] into Phase 3 development," with the drug.
In addition to the pill, Novo Nordisk also noted it has about 10 other obesity treatments currently in development.